Maximum-tolerated dose, toxicity, and efficacy of (131) I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma.
…, NB Levy, JP McGahan, Q Salako… - Journal of Clinical …, 1998 - ascopubs.org
PURPOSE Lym-1, a monoclonal antibody that preferentially targets malignant lymphocytes,
has induced remissions in patients with non-Hodgkin's lymphoma (NHL) when labeled with …
has induced remissions in patients with non-Hodgkin's lymphoma (NHL) when labeled with …
[PDF][PDF] 67Cu-21T-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma
…, DS Goldstein, GR Mirick, Q Salako… - Journal of Nuclear …, 1999 - Soc Nuclear Med
StudyDesign Eleven patients with histologically documented lymphoma of immunophenotypical
B-cell type with measurable lymphomatous disease, including at least one lesion of 2 …
B-cell type with measurable lymphomatous disease, including at least one lesion of 2 …
[PDF][PDF] Radioimmunotherapy for breast cancer using indium-lll/yttrium-90 BrE-3: results of a phase I clinical trial
…, RT O'Donnell, CM Richman, QA Salako… - Journal of Nuclear …, 1997 - Soc Nuclear Med
JSreast cancer strikes 182,000 people yearly in the United States, and 46,000 deaths a year
are attributable to this disease (/). Patients with localized disease can be cured by surgery …
are attributable to this disease (/). Patients with localized disease can be cured by surgery …
Comparison of 1, 4, 7, 10-tetraazacyclododecane-N, N', N'', N'''-tetraacetic acid (DOTA)-peptide-ChL6, a novel immunoconjugate with catabolizable linker, to 2 …
…, LA Kroger, CF Meares, CM Richman, Q Salako… - Clinical cancer research …, 1998 - AACR
Radioimmunotherapy using 131I-ChL6 antibody has shown promise in patients with breast
cancer. To enhance this potential, a novel ChL6 immunoconjugate that is catabolizable and …
cancer. To enhance this potential, a novel ChL6 immunoconjugate that is catabolizable and …
A comparative study of copper‐67 radiolabeling and kinetic stabilities of antibody‐macrocycle chelate conjugates
…, DP Greiner, SJ Denardo, GL Denardo, QA Salako… - Cancer, 1994 - Wiley Online Library
Background. The development of new chelating agents and radiolabeling protocols is
essential to progress in radioimmunotherapy with antibody‐chelate conjugates. Methods. …
essential to progress in radioimmunotherapy with antibody‐chelate conjugates. Methods. …
[PDF][PDF] Radioimmunolocalization of metastatic breast carcinoma using indium-111-methyl benzyl DTPA BrE-3 monoclonal antibody: phase I study
…, ME Noz, H Mizrachi, QA Salako… - Journal of Nuclear …, 1993 - Soc Nuclear Med
Imaging Quantitative planar imagingwas performed to determine phar macokinetics and tumor
localization (19, 20). All images were ob tamed using a large field of view gamma camera …
localization (19, 20). All images were ob tamed using a large field of view gamma camera …
[PDF][PDF] Yttrium-90-DOTA-peptide-chimeric L6 radioimmunoconjugate: efficacy and toxicity in mice bearing p53 mutant human breast cancer xenografts
…, MD Winthrop, LA Kroger, Q Salako… - Journal of Nuclear …, 1998 - Soc Nuclear Med
Methods: Groups of athymic mice bearing HBT 3477 xenografts received 4.1-to 14.1-MBq
doses of 90Y-DOTA-peptide-ChL6 intra venously. The lethal dose (LD) 50/30, general well-…
doses of 90Y-DOTA-peptide-ChL6 intra venously. The lethal dose (LD) 50/30, general well-…
Dosimetric evaluation of copper-64 in copper-67-2IT-BAT-Lym-1 for radioimmunotherapy
…, GL DeNardo, SJ DeNardo, Q Salako - The Journal of Nuclear …, 1996 - search.proquest.com
Copper-67 (67Cu) is an attractive radionuclide for radioimmuno-therapy because of its
favorable physical and biologic characteristics. Current supplies of 67Cu, however, contain as …
favorable physical and biologic characteristics. Current supplies of 67Cu, however, contain as …
[PDF][PDF] Pharmacokinetics of chimeric L6 conjugated to indium-111-and yttrium-90-DOTA-peptide in tumor-bearing mice
SJ DeNardo, GR Zhong, Q Salako, M Li… - Journal of Nuclear …, 1995 - Soc Nuclear Med
The pharmacoldnetlcsof 1111n-and@ ÂY-DOTA-PePtIde-ChL6 wereobtainedfor 5
daysafterinjectionin nudemicebeating HBT3477 xenographs. The results were compared withthe …
daysafterinjectionin nudemicebeating HBT3477 xenographs. The results were compared withthe …
Prelabeling of Chimeric Monoclonal Antibody L6 with 90Yttrium- and 111Indium-1,4,7,10-tetraazacyclododecane-N,N′,N″,N‴-tetraacetic acid (DOTA) Chelates …
M Li, CF Meares, Q Salako, DL Kukis, GR Zhong… - Cancer Research, 1995 - AACR
90 Y and 111 In have been attached to chimeric monoclonal antibody L6 with a bifunctional
chelating agent (DOTA-peptide isothiocyanate). The bifunctional chelating agent was …
chelating agent (DOTA-peptide isothiocyanate). The bifunctional chelating agent was …